迪哲医药 Mediaroom - PR Newswire APAC

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB...

2026-05-31 08:09 5365

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

* ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy a...

2026-05-29 20:52 4242

Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to...

2026-05-27 18:40 5074

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improv...

2026-03-21 19:26 7847

Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to...

2025-12-09 18:00 2384

Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC

SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed t...

2025-09-09 18:00 2649

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

* Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractor...

2025-08-06 19:02 2597

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approva...

2025-07-03 08:08 2973

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for it...

2025-06-19 18:08 3158

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in pe...

2025-06-12 18:13 2495

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

* DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic ...

2025-05-26 18:06 2746

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cel...

2025-05-15 18:09 3012

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

* DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poste...

2025-04-24 18:38 2864

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed t...

2025-04-01 18:18 3251

Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer

* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTC...

2025-03-20 18:00 2223

U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application

* If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment op...

2025-01-07 18:00 2705

Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer

Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety pr...

2024-12-11 18:05 2994

Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting

DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacok...

2024-12-09 18:00 2441

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an or...

2024-11-08 18:01 2563

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, O...

2024-10-13 16:04 3637

Latest News